[
  {
    "ts": null,
    "headline": "ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain",
    "summary": "ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX stock is rated a cautious Sell.",
    "url": "https://finnhub.io/api/news?id=1231bf04b8a4ca6d5e2355c9057fd64d49daa0aeafd3bad31e782c9bcb790746",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766085488,
      "headline": "ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain",
      "id": 137826481,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187784934/image_2187784934.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX stock is rated a cautious Sell.",
      "url": "https://finnhub.io/api/news?id=1231bf04b8a4ca6d5e2355c9057fd64d49daa0aeafd3bad31e782c9bcb790746"
    }
  },
  {
    "ts": null,
    "headline": "J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant",
    "summary": "JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.",
    "url": "https://finnhub.io/api/news?id=7828f6633e8b68f6c9175a7350c2202efdc8c947f743d203cf32853579c19e03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766080080,
      "headline": "J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant",
      "id": 137825235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.",
      "url": "https://finnhub.io/api/news?id=7828f6633e8b68f6c9175a7350c2202efdc8c947f743d203cf32853579c19e03"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
    "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
    "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766072400,
      "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
      "id": 137825231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
      "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661"
    }
  },
  {
    "ts": null,
    "headline": "5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments",
    "summary": "Social Security’s cost-of-living adjustments swing wildly year to year. The 2025 COLA came in at 2.5%, down from 3.2% in 2024 and 8.7% in 2023. For retirees counting on predictable income growth, this volatility creates planning challenges. The solution lies in dividend stocks that deliver consistent income growth regardless of Social Security. These five stocks ... 5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments",
    "url": "https://finnhub.io/api/news?id=194cdba4608a9917b65ac8142e6cc0354070bb3f75af7601e6fd2dfc6d790da6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766063973,
      "headline": "5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments",
      "id": 137821580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Social Security’s cost-of-living adjustments swing wildly year to year. The 2025 COLA came in at 2.5%, down from 3.2% in 2024 and 8.7% in 2023. For retirees counting on predictable income growth, this volatility creates planning challenges. The solution lies in dividend stocks that deliver consistent income growth regardless of Social Security. These five stocks ... 5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments",
      "url": "https://finnhub.io/api/news?id=194cdba4608a9917b65ac8142e6cc0354070bb3f75af7601e6fd2dfc6d790da6"
    }
  },
  {
    "ts": null,
    "headline": "Trump says Americans need to prepare for something the US ‘has never seen.’ How to get ready (and wealthy) in 2026",
    "summary": "Don't get left behind.",
    "url": "https://finnhub.io/api/news?id=4debee2300dd9c864d1f20ec9e7e9c45fced41c4343903685bcc3063c5450e79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766063580,
      "headline": "Trump says Americans need to prepare for something the US ‘has never seen.’ How to get ready (and wealthy) in 2026",
      "id": 137821412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Don't get left behind.",
      "url": "https://finnhub.io/api/news?id=4debee2300dd9c864d1f20ec9e7e9c45fced41c4343903685bcc3063c5450e79"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma",
    "summary": "Johnson & Johnson (NYSE: JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery.",
    "url": "https://finnhub.io/api/news?id=f7ba0fd46fca69b3852f16ff73da430754662786c82400036d9f73125f8d5ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766062800,
      "headline": "Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma",
      "id": 137821582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery.",
      "url": "https://finnhub.io/api/news?id=f7ba0fd46fca69b3852f16ff73da430754662786c82400036d9f73125f8d5ef6"
    }
  },
  {
    "ts": null,
    "headline": "Rate Cuts Make These 3 Income ETFs More Attractive Than Ever",
    "summary": "Low interest rates can give dividend stocks, real estate investment trusts, and corporate bonds a boost; these ETFs allow investors to capitalize.",
    "url": "https://finnhub.io/api/news?id=99cdc04c7ff14d229a88072937ea16f99de0934313ba83869a366bf158d33d82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766059440,
      "headline": "Rate Cuts Make These 3 Income ETFs More Attractive Than Ever",
      "id": 137831379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Low interest rates can give dividend stocks, real estate investment trusts, and corporate bonds a boost; these ETFs allow investors to capitalize.",
      "url": "https://finnhub.io/api/news?id=99cdc04c7ff14d229a88072937ea16f99de0934313ba83869a366bf158d33d82"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) and represents the",
    "url": "https://finnhub.io/api/news?id=f0932c11f93136598063ab6f647c7196a8f0c479719302e0e504e6e25f4194a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766059200,
      "headline": "U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer",
      "id": 137821583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) and represents the",
      "url": "https://finnhub.io/api/news?id=f0932c11f93136598063ab6f647c7196a8f0c479719302e0e504e6e25f4194a6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization",
    "summary": "Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=1dbb3245857310909c3d4a3e1de01f2484a23ad6a7b974a9083a7af05e84077d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766023746,
      "headline": "Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization",
      "id": 137818880,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=1dbb3245857310909c3d4a3e1de01f2484a23ad6a7b974a9083a7af05e84077d"
    }
  }
]